MaxCyte, Inc. Operating Cash Flow
MaxCyte, Inc. (MXCT) reported Operating Cash Flow of -$12.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- MaxCyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.66M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.17M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.69M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.46M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$34.41M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$27.61M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$21.69M.
- MaxCyte, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$14.78M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.83M 10-Q · filed 2026-08-13 | -$15.52M derived: sum of 3 quarters · filed 2026-08-13 | -$22.98M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$8.17M 10-Q · filed 2026-05-13 | -$10.86M derived: sum of 2 quarters · filed 2026-05-13 | -$18.32M derived: sum of 3 quarters · filed 2026-05-13 | -$28.17M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$10.15M derived: sum of 2 quarters · filed 2026-03-25 | -$20.00M derived: sum of 3 quarters · filed 2026-08-13 | -$34.41M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | -$7.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$17.31M derived: sum of 2 quarters · filed 2026-08-13 | -$31.72M 10-Q · filed 2025-11-13 | -$39.54M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$9.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$24.26M 10-Q · filed 2026-08-13 | -$32.08M derived: sum of 3 quarters · filed 2026-08-13 | -$36.48M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$14.41M 10-Q · filed 2026-05-13 | -$22.23M derived: sum of 2 quarters · filed 2026-05-13 | -$26.62M derived: sum of 3 quarters · filed 2026-05-13 | -$31.46M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$7.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$12.21M derived: sum of 2 quarters · filed 2026-03-25 | -$17.05M derived: sum of 3 quarters · filed 2026-03-25 | -$27.61M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | -$4.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$9.22M derived: sum of 2 quarters · filed 2025-11-13 | -$19.79M 10-Q · filed 2025-11-13 | -$18.81M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$4.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$15.40M 10-Q · filed 2025-08-06 | -$14.42M derived: sum of 3 quarters · filed 2025-08-06 | -$22.66M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | -$10.56M 10-Q · filed 2025-05-08 | -$9.58M derived: sum of 2 quarters · filed 2025-05-08 | -$17.82M derived: sum of 3 quarters · filed 2025-05-08 | -$27.93M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $981.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$7.26M derived: sum of 2 quarters · filed 2025-03-11 | -$17.36M derived: sum of 3 quarters · filed 2025-03-11 | -$21.69M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | -$8.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$18.34M derived: sum of 2 quarters · filed 2024-11-06 | -$22.67M 10-Q · filed 2024-11-06 | -$22.67M 10-Q · filed 2023-11-08 | -$28.75M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$10.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$14.43M 10-Q · filed 2024-08-06 | -$14.43M 10-Q · filed 2023-08-09 | -$20.52M derived: sum of 3 quarters · filed 2024-08-06 | -$26.44M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | -$4.32M 10-Q · filed 2024-05-07 | -$4.32M 10-Q · filed 2023-05-10 | -$10.41M derived: sum of 2 quarters · filed 2024-05-07 | -$16.33M derived: sum of 3 quarters · filed 2024-05-07 | -$15.41M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | -$6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$12.01M derived: sum of 2 quarters · filed 2024-03-12 | -$11.09M derived: sum of 3 quarters · filed 2024-03-12 | -$14.78M 10-K · filed 2024-03-12 | -$14.78M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | -$5.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$5.00M derived: sum of 2 quarters · filed 2023-11-08 | -$8.70M 10-Q · filed 2023-11-08 | -$9.66M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $918.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.78M 10-Q · filed 2023-08-09 | -$3.74M derived: sum of 3 quarters · filed 2023-08-09 | -$4.43M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | -$3.69M 10-Q · filed 2023-05-10 | -$4.65M derived: sum of 2 quarters · filed 2023-05-10 | -$5.34M derived: sum of 3 quarters · filed 2023-05-10 | -$9.73M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$960.25K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$1.65M derived: sum of 2 quarters · filed 2023-03-15 | -$6.04M derived: sum of 3 quarters · filed 2023-03-15 | -$10.68M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$690.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$5.08M derived: sum of 2 quarters · filed 2022-11-09 | -$9.72M 10-Q · filed 2022-11-09 | -$11.63M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$9.03M 10-Q · filed 2022-08-10 | -$10.94M derived: sum of 3 quarters · filed 2022-08-10 | -$11.77M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$4.64M 10-Q · filed 2022-05-09 | -$6.55M derived: sum of 2 quarters · filed 2022-05-09 | -$7.38M derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$2.74M derived: sum of 2 quarters · filed 2022-03-22 | -$8.78M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | -$830.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$6.87M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | -$6.04M 10-Q · filed 2021-09-13 | |||||||
| 2019-12-31 | -$8.80M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |